Abstract
Heme oxygenase-1 (HO-1) catalyzes the degradation of heme to generate carbon monoxide, biliverdin and free iron. Increased HO-1 levels constitute an anatomopathological feature of many neurological diseases, such as neurodegenerative disorders and brain infections, which correlate with exacerbated oxidative stress and inflammation. It is generally accepted that the elevated HO-1 levels represent an attempt to restore redox homeostasis and to down-modulate inflammation. However, experimental observations indicate that the extent of HO-1 induction may be critical because excessive heme degradation may result in toxic levels of CO, bilirubin and, more importantly, iron. Pharmacological modulation of HO-1 levels in the brain, within therapeutic limits, shows promising results in models of Alzheimers (AD), Parkinsons (PD) and of infectious diseases, such as malaria. A more complete understanding on how HO-1 is involved in the pathogenesis of neurological diseases will be essential to develop therapeutic approaches. In the next coming years we will witness the description of chemicals, drugs or dietary products that cross the blood brain barrier efficiently, activate HO-1 expression, and achieve neuroprotective and anti-inflammatory effects in vivo.
Keywords: Heme oxygenase-1, oxidative stress, neurodegenerative diseases, inflammation, microglia
Current Pharmaceutical Design
Title: Heme Oxygenase-1 as a Therapeutic Target in Neurodegenerative Diseases and Brain Infections
Volume: 14 Issue: 5
Author(s): Antonio Cuadrado and Ana I. Rojo
Affiliation:
Keywords: Heme oxygenase-1, oxidative stress, neurodegenerative diseases, inflammation, microglia
Abstract: Heme oxygenase-1 (HO-1) catalyzes the degradation of heme to generate carbon monoxide, biliverdin and free iron. Increased HO-1 levels constitute an anatomopathological feature of many neurological diseases, such as neurodegenerative disorders and brain infections, which correlate with exacerbated oxidative stress and inflammation. It is generally accepted that the elevated HO-1 levels represent an attempt to restore redox homeostasis and to down-modulate inflammation. However, experimental observations indicate that the extent of HO-1 induction may be critical because excessive heme degradation may result in toxic levels of CO, bilirubin and, more importantly, iron. Pharmacological modulation of HO-1 levels in the brain, within therapeutic limits, shows promising results in models of Alzheimers (AD), Parkinsons (PD) and of infectious diseases, such as malaria. A more complete understanding on how HO-1 is involved in the pathogenesis of neurological diseases will be essential to develop therapeutic approaches. In the next coming years we will witness the description of chemicals, drugs or dietary products that cross the blood brain barrier efficiently, activate HO-1 expression, and achieve neuroprotective and anti-inflammatory effects in vivo.
Export Options
About this article
Cite this article as:
Cuadrado Antonio and Rojo I. Ana, Heme Oxygenase-1 as a Therapeutic Target in Neurodegenerative Diseases and Brain Infections, Current Pharmaceutical Design 2008; 14 (5) . https://dx.doi.org/10.2174/138161208783597407
DOI https://dx.doi.org/10.2174/138161208783597407 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Application of Dietary Polyphenols from Red Wine to Attaining Healthy Ageing
Current Topics in Medicinal Chemistry Mechanisms of Action of Metformin in Type 2 Diabetes and Associated Complications: An Overview
Mini-Reviews in Medicinal Chemistry Selective Acetyl- and Butyrylcholinesterase Inhibitors Reduce Amyloid-β Ex Vivo Activation of Peripheral Chemo-cytokines From Alzheimer's Disease Subjects: Exploring the Cholinergic Anti-inflammatory Pathway
Current Alzheimer Research The Urokinase Receptor in the Central Nervous System
CNS & Neurological Disorders - Drug Targets New Achievements in Bioinformatics Prediction of Post Translational Modification of Proteins
Current Topics in Medicinal Chemistry Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents
Current Medicinal Chemistry A Proteome-Level Computational Biology Insight on Sequence Based Aggregation Propensity Profile of Human Hydrolase Structural Enzymes
Current Biotechnology SPECT Radiopharmaceuticals for Dementia
Current Radiopharmaceuticals Contrasting Roles of the Galectin-3 in the Schizophrenia Onset, Clinical Presentation, and Somatic Comorbidity
Current Topics in Medicinal Chemistry Modulation of Apoptosis in Acute Ischemic Stroke as Treatment Challenges
Current Immunology Reviews (Discontinued) Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Will it Ever Become Possible to Prevent Dopaminergic Neuronal Degeneration?
CNS & Neurological Disorders - Drug Targets Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets NMR Structural Studies of Human Cellular Prion Proteins
Current Topics in Medicinal Chemistry Role of Mitochondrial Translocator Protein (18 kDa) on Mitochondrial- Related Cell Death Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Enriching One’s Environment in the Face of Cognitive and Functional Loss
Current Neurovascular Research Nanomedicine and its Application in Treatment of Microglia-mediated Neuroinflammation
Current Medicinal Chemistry Is Alpha-Synuclein Pathology a Target for Treatment of Neurodegenerative Disorders?
Current Alzheimer Research Experimental Research on Nitric Oxide and the Therapy of Alzheimer Disease: A Challenging Bridge
CNS & Neurological Disorders - Drug Targets Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine